Results 1 to 10 of about 7,463 (182)
Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center [PDF]
ClinicoEconomics and Outcomes Research, 2016 Michele Carron, Fabio Baratto, Francesco Zarantonello, Carlo Ori Department of Medicine, Anesthesiology and Intensive Care, University of Padova, Padova, Italy Objective: The aim of the study is to evaluate the clinical and economic impact of introducing
Carron M +3 more
doaj +3 more sources
Prediction of Optimal Reversal Dose of Sugammadex after Rocuronium Administration in Adult Surgical Patients [PDF]
Anesthesiology Research and Practice, 2014 The objective of this study was to determine the point after sugammadex administration at which sufficient or insufficient dose could be determined, using first twitch height of train-of-four (T1 height) or train-of-four ratio (TOFR) as indicators ...
Shigeaki Otomo +6 more
doaj +3 more sources
Journal of PeriAnesthesia Nursing, 2016 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J +2 more
+8 more sources
Postoperative mortality in patients with end-stage renal disease according to the use of sugammadex: a single-center retrospective propensity score matched study [PDF]
Anesthesia and Pain Medicine, 2022 Background Clearance of the sugammadex-rocuronium complex is limited to renal excretion. There are restrictions on the use of sugammadex in patients with severe renal impairment.
Sanghoon Song +10 more
doaj +1 more source
Critical Care and Resuscitation, 2013 Sugammadex is the first selective antagonist to reverse neuromuscular blockade induced by rocuronium and vecuronium. The mechanism by which sugammadex works is superior to current neuromuscular block reversal strategies in terms of speed, efficacy and side effects.
Dharshi, Karalapillai +2 more
+6 more sources
Effects of rocuronium, sugammadex and rocuronium-sugammadex complex on coagulation in rats [PDF]
Revista Brasileira de Anestesiologia, 2021 Background and objectives: Sugammadex is an alternative pharmacological drug capable of reversing neuromuscular blockades without the limitations that are presented by anticholinesterase drugs.
Ismar Lima Cavalcanti +6 more
doaj +3 more sources
Anaphylaxis induced by sugammadex and sugammadex-rocuronium complex -a case report- [PDF]
Korean Journal of Anesthesiology, 2020 Background In sugammadex-induced anaphylaxis, sugammadex and/or sugammadex-rocuronium complex have possible allergenic epitope. Case We report a case of sugammadex-induced anaphylaxis during general anesthesia in a 60-year-old male undergoing orthopedic ...
Shu Chung Choi +3 more
doaj +1 more source
What we need to know and do on sugammadex usage in pregnant and lactating women and those on hormonal contraceptives [PDF]
Anesthesia and Pain Medicine, 2023 Sugammadex is a chemically modified γ-cyclodextrin that is used as a selective reversal agent for steroidal neuromuscular blockade. The use of sugammadex has greatly increased globally; however, little is known about its potential adverse effects in ...
Wangseok Do, Ah-Reum Cho
doaj +1 more source
Journal of Medical Case Reports, 2021 Background Sugammadex is a synthetic γ-cyclodextrin derivative designed to selectively bind to steroidal neuromuscular blocking agents and reverse their effects.
Tatsuo Horiuchi +6 more
doaj +1 more source
Journal of the Formosan Medical Association, 2022 Sugammadex is a direct reversal agent of aminosteroid muscle relaxants, particularly rocuronium, with promptly and completely reverse of deep neuromuscular block (NMB), which allows better surgical conditions. Sugammadex exhibits advantages over indirect
Hsiao-Cheng Chang +4 more
doaj +1 more source